Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

An international team involving the Institute of Chemical Research, a joint center of the University of Seville and the ...

Warner Bros. Discovery said it is open to a sale as it expands its strategic review. CNBC's David Faber breaks down the latest details. Judge Strikes Down Gun Ban in Major Ruling Urgent warning issued ...

The drug development pipeline is a costly and lengthy process. Identifying high-quality "hit" compounds—those with high potency, selectivity, and favorable metabolic properties—at the earliest stages ...

Great. Good morning, everyone. I'm Alexandra Byrne. I'm a reporter at GenomeWeb, and I will be your moderator for today's webinar. The title of today's webinar is beyond the genome: Measuring ...

Researchers at Harvard Medical School developed a tool that uses artificial intelligence to accelerate drug discovery and development. The new technology, called PDGrapher, applies machine learning to ...

Drug discovery is becoming more personalized, and the methods used to generate therapeutic insights are advancing alongside it. Spatial biology tools let researchers interrogate tissue function, cell ...

WASHINGTON (7News) — Artificial intelligence is poised to dramatically reshape the process of developing and approving new medicines, according to industry experts. Traditionally, the path from drug ...

UB researcher Thomas Grant has been awarded a $2.18 million federal grant to create a new artificial intelligence-powered tool that improves scientists’ understanding of how proteins move and change ...

A new sustainable method to produce pharmaceuticals could help to lower prescription drug costs in the U.S. This chemical discovery by the University of Maine, the USDA Forest Products Laboratory and ...

Discover how Optibrium is transforming early-stage drug discovery through AI-powered software, generative chemistry, and 3D modelling. In this interview, Matt Segall, CEO at Optibrium, shares insights ...